Natco Pharma Completes Adcock Ingram Delisting from JSE; Acquires 35.75% Stake Worth US$226 Million

Hyderabad, November 12, 2025: Natco Pharma Limited announced the successful delisting of Adcock Ingram Holdings Limited, one of South Africa’s oldest pharmaceutical companies, from the Johannesburg Stock Exchange (JSE). As part of the move, Natco Pharma has acquired a 35.75% stake in Adcock Ingram for approximately US$226 million.

Strategic Acquisition Strengthens Global Presence

In July 2025, Natco Pharma offered ZAR 75 (approximately US$4.36) per share to Adcock Ingram’s minority shareholders. The proposal received overwhelming approval in October 2025, paving the way for Natco’s strategic acquisition. This move strengthens Natco’s presence in the South African pharmaceutical market, providing direct access to one of the continent’s largest healthcare networks.

Adcock Ingram, established in 1891, is ranked second in South Africa’s private and public pharmaceutical markets. Its portfolio spans prescription, OTC, consumer, and hospital products, including well-known brands such as Panado, Myprodol, Epi-Max, Citro-Soda, and Allergex.

Management Commentary

The CEO of Natco Pharma, Rajeev Nannapaneni, said that this acquisition is a significant step in the company’s strategic growth plan across the globe. The team at Natco is committed to preserving the rich legacy of Adcock Ingram. He also said, “We are also poised to enhance its capabilities to better serve the healthcare needs of communities across Africa and beyond.”

Share price Update

The share price of Natco Pharma closed with a 3.91% gain today. The Natco Pharma shares have dipped 40% in the last year, down 1,8% in the last six months, and gained 0.75% in the last 5 days.

Natco Pharma, headquartered in Hyderabad and founded in 1981, is engaged in the research, manufacturing, and global marketing of formulations and active pharmaceutical ingredients (APIs). The company operates in over 50 countries worldwide.

REF: https://nsearchives.nseindia.com/corporate/NATCOPHARM_12112025150205_PressRelease_12112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations